Answer
The oral suspension described here is licensed for neurogenic detrusor overactivity in children and adolescents aged 2 to 18 years. The film-coated tablets described here are not licensed for children.
Sources for this answer
- Solifenacin succinate Umedica 5 mg film-coated tablets — Current selected SmPCemc · Summary of Product Characteristics
- Solifenacin succinate 1 mg/ml oral suspension — Current selected SmPCemc · Summary of Product Characteristics
General medicine information. Follow the instructions for your own medicine and speak to a pharmacist or clinician about your individual circumstances.